This study uncovers clonal lymphocyte expansions and JAK-STAT pathway mutations as key drivers of refractory celiac disease, suggesting a shared pathogenic continuum between RCD1 and RCD2 while cautioning against JAK inhibitor monotherapy due to resistance risks.